Search results for " Embolism"

showing 10 items of 311 documents

Prevention, diagnosis and treatment of venous thromboembolism

2020

Machaj Dominik, Cyboran Katarzyna, Płaczek Alicja, Baran Marlena, Wojnowski Michał. Prevention, diagnosis and treatment of venous thromboembolism. Journal of Education, Health and Sport. 2020;10(6):88-94. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.06.009 https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.06.009 https://zenodo.org/record/3889858 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2020; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Ope…

medicine.medical_specialtypulmonary embolismDeep veinvenous thromboembolismLumen (anatomy)Thrombophiliadeep vein thrombosisEducationmedicinemedia_common.cataloged_instancecardiovascular diseasesThrombusEuropean unionVeinmedia_commonbusiness.industryRmedicine.diseaseLThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureGV557-1198.995MedicinebusinessSportsJournal of Education, Health and Sport
researchProduct

Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraind…

2018

Introduction Intravenous thrombolysis is the treatment of choice in patients presenting with high- and intermediate-risk pulmonary embolism. The role of percutaneous mechanical pulmonary thrombectomy (PMPT) is not fully established, although selected patients can be managed with this method. Aim This open-label single-centre prospective pilot study was aimed at assessing the feasibility of PMPT for the treatment of severe pulmonary embolism in a Polish hospital. We also evaluated the safety and efficacy of such management. Material and methods We managed 7 patients, aged 52.7 ±16.6 years, presenting with high- and intermediate-risk pulmonary embolism (4 patients with class 5 and one patient…

medicine.medical_specialtypulmonary embolismPercutaneousUrologymedicine.medical_treatmentEmbolectomy030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinepulmonary arteryPulmonary thrombectomymedicine.arteryFibrinolysismedicine030212 general & internal medicinethromboembolic diseaseOriginal Paperbusiness.industryGastroenterologyObstetrics and GynecologyThrombolysismedicine.diseaseSurgeryPulmonary embolismmechanical thrombectomy systemPneumoniaPulmonary arterySurgerybusinessVideosurgery and Other Miniinvasive Techniques
researchProduct

Variation of platelet function in clinical phenotypes of acute venous thromboembolism – Results from the GMP‐VTE project

2022

Background The role of platelets in the pathogenesis of venous thromboembolism (VTE) is receiving increasing attention; however, limited information is available on platelet function in the acute phase of the disease. Objective To characterize platelet function according to VTE phenotypes. Patients/Methods In total, 154 subjects (isolated pulmonary embolism [iPE], n = 28; isolated deep vein thrombosis [iDVT], n = 35; DVT+PE, n = 91) were included. In this study platelet function analyzer (PFA)-200, light transmission aggregometry (LTA), thrombin generation (TG) in presence (PRP) and absence (PFP) of platelets and platelet flow cytometry were investigated. LASSO regression was used to select…

medicine.medical_specialtypulmonary embolismPlatelet Function TestsPULMONARY-EMBOLISMplatelet functionDeep veinvenous thromboembolism610 MedizinDETERMINANTSGastroenterologydeep vein thrombosisDISEASEPathogenesischemistry.chemical_compoundPlatelet degranulationRISK-FACTOR610 Medical sciencesInternal medicineHumansMedicinePlateletcardiovascular diseasesPOPULATIONVenous Thrombosisbusiness.industryHematologymedicine.diseaseABSENCEThrombosisPREDICTSPulmonary embolismASPIRINAdenosine diphosphatePhenotypeEpinephrinemedicine.anatomical_structurechemistrythrombin generationVOLUMEbusinessmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Prevalence of pulmonary embolism in 127 945 autopsies performed in cancer patients in the United States between 2003 and 2019

2021

Abstract Background Pulmonary embolism (PE) is a potentially fatal disease, but data on the incidence of fatal PE in cancer patients are scant. Objective We sought to estimate the proportion of cancer patients with PE at autopsy. Methods For this retrospective cohort study, all autopsy reports of cancer patients were retrieved from PALGA: Dutch Pathology Registry and used for data extraction. The primary outcome was PE at time of autopsy, defined as any clot obstructing a pulmonary artery. The secondary outcome was venous thromboembolism, defined as the composite of thrombotic PE, deep vein thrombosis, splanchnic vein thrombosis, or internal jugular vein thrombosis. Results A total of 9571 …

medicine.medical_specialtypulmonary embolismvenous thromboembolism2720 Hematology610 Medicine & healthAutopsyautopsyNeoplasmsInternal medicineEpidemiologyPrevalencemedicineHumanscancerbusiness.industry10031 Clinic for AngiologyCancerOriginal ArticlesHematologymedicine.diseasemortalityUnited StatesPulmonary embolismTHROMBOSISOriginal ArticleepidemiologybusinessJournal of Thrombosis and Haemostasis
researchProduct

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism

2019

Abstract Introduction VTE‐BLEED is a validated score for identification of patients at increased risk of major bleeding during extended anticoagulation for venous thromboembolism (VTE). It is unknown whether VTE‐BLEED high‐risk patients also have an increased risk for recurrent VTE, which would limit the potential usefulness of the score. Methods This was a post hoc analysis of the randomized, double‐blind, placebo‐controlled PADIS‐PE trial that randomized patients with a first unprovoked pulmonary embolism (PE) initially treated during 6 months to receive an additional 18‐month of warfarin vs. placebo. The primary outcome of this analysis was recurrent VTE during 2‐year follow‐up after ant…

medicine.medical_specialtyrecurrencemedicine.drug_classvenous thromboembolismInternal medicinemedicineCumulative incidencecardiovascular diseasesanticoagulation therapylcsh:RC633-647.5business.industryAnticoagulantHazard ratioWarfarinlcsh:Diseases of the blood and blood-forming organsprediction scoreHematologyBleedbleedingequipment and suppliesmedicine.diseaseConfidence intervalPulmonary embolismDiscontinuationOriginal ArticlebusinessOriginal Articles: Thrombosismedicine.drugResearch and Practice in Thrombosis and Haemostasis
researchProduct

Pulmonary Embolism: Contemporary Medical Management and Future Perspectives

2018

Pulmonary embolism (PE) contributes substantially to the global disease burden. A key determinant of early adverse outcomes is the presence (and severity) of right ventricular dysfunction. Consequently, risk-adapted management strategies continue to evolve, tailoring acute treatment to the patients' clinical presentation, hemodynamic status, imaging and biochemical markers, and comorbidity. For subjects with hemodynamic instability or 'high-risk' PE, immediate systemic reperfusion treatment with intravenous thrombolysis is indicated; emerging approaches such as catheter-directed pharmacomechanical reperfusion might help to minimize the bleeding risk. Currently, direct, non-vitamin K-depende…

medicine.medical_specialtythrombolysispulmonary embolismmedicine.medical_treatmentvenous thromboembolismHemodynamicsReview Articlerisk stratification030204 cardiovascular system & hematologyVitamin kdirect oral anticoagulants03 medical and health sciences0302 clinical medicinemedicine030212 general & internal medicineIntensive care medicineDisease burdenbusiness.industryGeneral MedicineThrombolysismedicine.diseaseComorbidityRight ventricular dysfunctionReview articlePulmonary embolismright ventricular dysfunctionbusinessAnnals of Vascular Diseases
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Infective Endocarditis: Preliminary Results of a Cohort Study in the Southern Italian Population.

2020

Background Infective endocarditis (IE) is an uncommon disease with an involved interplay of clinical and surgical team management. We aimed to define diagnosis parameters and delineate in-hospital management in patients with IE admitted in a tertiary hospital of Southern Italian. Materials and methods Fifty-six consecutive patients (42 males, 14 females; age range: 34-85 years) admitted for IE in the Infectious Diseases, Cardiac Surgery, and Cardiology units, between January 2011 and August 2017, were enrolled. Demographic data, mortality, comorbidities, specimen type, microscopy results, special histological staining performed, and antimicrobial therapy were collected and analyzed. Any com…

microorganismmedicine.medical_specialtyArterial embolismcomplicationsCardiologyunivariate analysicandida endocarditi030204 cardiovascular system & hematologyendocarditi03 medical and health sciences0302 clinical medicinematlabInternal medicinemedicinegenderEndocarditisBlood cultureadult cardiac surgerymicroorganismsSurgical teamUnivariate analysismedicine.diagnostic_testbusiness.industryGeneral Engineeringmedicine.diseaseCardiac surgeryunivariate analysiscandida endocarditismultivariate analysisInfective endocarditismulti-drug resistant bacteriaendocarditisbusiness030217 neurology & neurosurgeryCohort studyCureus
researchProduct

Lemierre Syndrome associated with dental infections : report of one case and review of the literature

2007

The first publication on Lemierre Syndrome appears in 1936 by Lemierre. It is defined as an ?oropharynx bacterial infection characterized by the thrombophlebitis in the internal jugular vein, derived in a systemic septic embolism?. In 81% of the cases, the Fusobacterium necrophorum is the most frequent etiologic agent. Fever is the most common symptom, but it can depending on the primary infection, tonsillitis, mastoiditis or odontogenic infection. According to the literature the mortality is very low, but with a significant morbidity, that is why the diagnosis and early treatment is very important. The diagnosis it´s clinical, even though the CT scan and other diagnosis methods (echography…

septic pulmonary embolisminternal jugular venous thrombosisUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS [UNESCO]Lemierre syndromeinfection
researchProduct